News headlines about Catabasis Pharmaceuticals (NASDAQ:CATB) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catabasis Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.9099787766313 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
- Catabasis Pharmaceuticals, Inc. (CATB)- Stocks Hammered on Sluggish Data – NASDAQ Times (nasdaqtimes.com)
- Cowen and Company Reiterates “Market Perform” Rating for Catabasis Pharmaceuticals, Inc. (CATB) (americanbankingnews.com)
- Catabasis Pharmaceuticals, Inc. (CATB) stock forward in overbought space? – Voice Of Analysts (analystsbuzz.com)
- Catabasis Pharmaceuticals, Inc. (CATB) Given New $3.50 Price Target at Citigroup Inc. (americanbankingnews.com)
- Catabasis’ DMD Candidate Slows Disease Progression, Stock Up (finance.yahoo.com)
A number of equities research analysts have recently commented on the company. Citigroup Inc. set a $3.50 target price on Catabasis Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday. Oppenheimer Holdings, Inc. boosted their price objective on Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the company an “outperform” rating in a research note on Thursday. CIBC restated an “outperform” rating and issued a $7.00 price objective (up from $4.00) on shares of Catabasis Pharmaceuticals in a research note on Thursday. HC Wainwright boosted their price objective on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Monday, August 14th. Finally, Cowen and Company restated a “market perform” rating and issued a $2.00 price objective on shares of Catabasis Pharmaceuticals in a research note on Friday. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Catabasis Pharmaceuticals has a consensus rating of “Buy” and an average target price of $5.42.
Shares of Catabasis Pharmaceuticals (NASDAQ CATB) opened at 2.49 on Friday. The company has a 50-day moving average price of $2.00 and a 200-day moving average price of $2.00. Catabasis Pharmaceuticals has a 52 week low of $1.08 and a 52 week high of $5.51. The company’s market capitalization is $55.98 million.
Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. Analysts predict that Catabasis Pharmaceuticals will post ($1.39) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://transcriptdaily.com/2017/10/08/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-catabasis-pharmaceuticals-catb-stock-price.html.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.